Kala Frances Schilter

Dr. Kala Frances Schilter

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
SKSakshi Khurana
Sakshi Khurana
VKViriya Keo
Viriya Keo
ALAlexandra Larson
Alexandra Larson
VUVindhya Udhane
Vindhya Udhane
JAJennifer N Adams
Jennifer N Adams
Honey V Reddi, PhD, FACMGHoney V Reddi, PhD, FACMG
Honey V Reddi, PhD, FACMG
Background/Objectives: The latest National Comprehensive Cancer Network (NCCN) Central Nervous System (CNS) Guidelines recommend utilizing next-generation sequencing (NGS) to enable comprehensive genomic profiling (CGP) as the preferred approach for molecular characterization of central nervous system (CNS) malignancies. CNS malignancies present distinct challenges due to the infeasibility of tissue-based testing for many patients and the restrictive nature of the blood–brain barrier (BBB) making plasma-based liquid biopsy an ineffective alternative. Recent advances in liquid biopsy have extended molecular testing beyond plasma to include cerebrospinal fluid (CSF), which serves as a valuable source for tumor-derived nucleic acids. Methods: The Belay Summit™ 2.0 is a high-throughput CGP assay capable of detecting multiple variant types, including single nucleotide variants (SNVs) and small insertion and deletions (Indels), copy number variations (CNVs), gene fusions, splice variants, and immunotherapy biomarkers such as microsatellite instability (MSI) and tumor mutational burden (TMB). This study details the analytical and clinical validation of Summit™ 2.0 to assess its technical performance and clinical sensitivity. Analytical validation was conducted using 68 specimens, demonstrating robust and reproducible detection of all variant types with 15 ng of CSF-derived total nucleic acid (tNA). Results: The analytical sensitivity of the Belay Summit™ 2.0 assay for SNVs and Indels was determined to be 96.7% with a 100% limit of detection (LoD) at a variant allele frequency of 0.3%. Clinical validity was evaluated across a cohort of 118 CSF specimens, including both primary and metastatic CNS tumors, demonstrating 96% sensitivity and 98% specificity. Conclusions: These findings support the use of the Belay Summit™ 2.0 assay for accurate and reproducible genomic profiling of CNS tumors using tumor-derived nucleic acids from CSF in patients for whom tissue-based testing is considered infeasible, unsafe, or not deemed by the prescribing physician to be clinically appropriate.

1 January 2022 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Open access
PDF file
COChinelo P Onyenekwu
Chinelo P Onyenekwu
ACAshley M Cunningham
Ashley M Cunningham
KSKala Frances Schilter
Kala Frances Schilter
Honey V Reddi, PhD, FACMGHoney V Reddi, PhD, FACMG
Honey V Reddi, PhD, FACMG
ECElizabeth J Cochran
Elizabeth J Cochran

11 October 2025 in Diseases
Verified
Journal Article
Open access
PDF file
MYMichael Youssef
Michael Youssef
ALAlexandra Larson
Alexandra Larson
VUVindhya Udhane
Vindhya Udhane
VKViriya Keo
Viriya Keo
KSKala Frances Schilter
Kala Frances Schilter
Honey V Reddi, PhD, FACMGHoney V Reddi, PhD, FACMG
Honey V Reddi, PhD, FACMG
A woman in her 40s with a history of ER/PR+, HER2-negative breast cancer presented with a seizure three years after mastectomy. Magnetic resonance imaging (MRI) revealed a right caudate head mass, which was concerning for either high-grade glioma or metastatic disease, but biopsy was deemed too high risk. Cerebrospinal fluid (CSF) tumor-derived DNA (tDNA) analysis by next-generation sequencing (NGS) was ordered, revealing a gain-of-function variant in PIK3CA, ERBB2 copy number gain, and high aneuploidy, findings consistent with breast cancer brain metastasis. Based on these results, the patient was treated with stereotactic radiosurgery (SRS) followed by trastuzumab deruxtecan, a HER2-targeted therapy. This case highlights the diagnostic and therapeutic value of CSF tDNA analysis in central nervous system (CNS) lesions when biopsy is not feasible. The report also illustrates how clonal evolution, such as acquired ERBB2 amplification, can occur in metastatic disease and influence treatment decisions.

17 April 2026 in Cancers
Verified
Journal Article
Open access
PDF file
QNQian Nie
Qian Nie
KSKala Frances Schilter
Kala Frances Schilter
ALAlexandra Larson
Alexandra Larson
VUVindhya Udhane
Vindhya Udhane
VKViriya Keo
Viriya Keo
Honey V Reddi, PhD, FACMGHoney V Reddi, PhD, FACMG
Honey V Reddi, PhD, FACMG
Background: Evaluation of chromosome aneuploidy and gene-level copy number alterations for diagnosis, prognosis, and therapeutic decision-making in solid tumors is the standard of care. Chromosomal microarray (CMA), next-generation sequencing (NGS), immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH) are the gold standard for detecting these variants in tumor tissue. In contrast to most solid tumors, cancers of the central nervous system (CNS) pose a unique challenge for effective detection via plasma due to the blood–brain barrier (BBB), with the additional challenges of brain biopsy or surgery being highly invasive and posing a significant risk to the patient. The Belay Ascent™ liquid biopsy test uses low-pass whole-genome sequencing (LP-WGS) to report on chromosome arm-level aneuploidy and gene-level copy number variants (CNVs) in cerebrospinal fluid (CSF) to inform diagnosis, prognosis, and therapeutic decision-making in CNS tumors. Methods: This study presents the equivalence of Ascent™ in detecting chromosome arm-level aneuploidy and gene-level CNVs using 48 tissue specimens followed by a clinical validation using a cohort of 32 CSF specimens with matched tissue-based tumor profiling information. Results: Equivalence of Ascent™ in detecting chromosome arm-level aneuploidy and gene-level CNVs using 48 tissue specimens was shown to have 100% and 97% positive percent agreement (PPA), respectively, compared to the gold standard of CMA/NGS. The validation cohort of 32 CSF specimens demonstrated 78% and 90% PPA for aneuploidy and gene-level CNVs, respectively. Clinical impact of Ascent™ was demonstrated, with 243 production cases able to inform the diagnosis and management of CNS tumors with high accuracy. Conclusions: Given the paucity of cells in CSF, limiting the use of karyotyping, CMA, IHC, and FISH, the Belay Ascent™ test provides a highly sensitive novel minimally invasive method for the evaluation of chromosome aneuploidy and gene-level CNVs in CSF.

1 January 2023 in Biomarker Insights
Verified
Journal Article
Open access
KSKala Frances Schilter
Kala Frances Schilter
SDSarah Dubay
Sarah Dubay
MSMatt Stachowiak
Matt Stachowiak
AKAlysia Kaplan
Alysia Kaplan
ASAbby Stauffenger
Abby Stauffenger
Honey V Reddi, PhD, FACMGHoney V Reddi, PhD, FACMG
Honey V Reddi, PhD, FACMG
Precision medicine for oncology requires the evaluation of variants identified in molecular profiling of solid tumors and hematologic malignancies. This includes evaluation of pre-analytical and postanalytical quality metrics, variant interpretation, classification, and tiering as outlined in established guidelines, association with clinical significance such as FDA approved drugs and clinical trials, and finally comprehensive reporting. This study documents our experience with the customization and implementation of a software platform that facilitates these requirements for effective reporting of somatic variants.

22 July 2026 in The Oncologist
Verified
Journal Article
Open access
JSJason B Sherman
Jason B Sherman
THThaddeus D Harbaugh
Thaddeus D Harbaugh
ASAlexander Sisto
Alexander Sisto
ZSZohaib Sherwani
Zohaib Sherwani
IJImraan Jan
Imraan Jan
MVMorana Vojnic
Morana Vojnic
Background: Diffuse midline glioma (DMG) with the H3K27M mutation is an aggressive WHO grade 4 central nervous system tumor characterized by diffuse infiltration of midline structures and a poor prognosis. Molecular characterization is essential for diagnosis and treatment planning; however, obtaining tissue can be infeasible, particularly in anatomically inaccessible locations or medically complex situations, like pregnancy. Patient presentation: A 34-year-old G2P1 woman at 19 weeks’ gestation presented with progressive right-sided numbness and weakness. Magnetic resonance imaging demonstrated an infiltrative lesion in the left midbrain extending to the pons and thalamus with intralesional hemorrhage. Differential considerations included diffuse midline glioma and inflammatory demyelinating disease. Molecular findings: Because of the lesion location and concerns regarding stereotactic biopsy during pregnancy, cerebrospinal fluid (CSF) next-generation sequencing was pursued. CSF profiling identified an H3K27M mutation, establishing the diagnosis of DMG. Management and outcome: Following multidisciplinary discussion involving neuro-oncology, neurology, neurosurgery, radiation oncology, and maternal-fetal medicine, the patient underwent fractionated radiotherapy beginning at 22 weeks’ gestation using pregnancy-shielding techniques. Postpartum dordaviprone (ONC201) therapy was initiated and well tolerated. Follow-up imaging demonstrated radiographic improvement and neurological stabilization, with ongoing response at 12 months post-diagnosis. Conclusions: The case highlights the utility of CSF liquid biopsy in establishing a molecular diagnosis of diffuse midline glioma when tissue biopsy is contraindicated or deferred. The case also demonstrates how molecular profiling can guide precision oncology in medically complex situations like pregnancy.